GlassScriptPhysician profile
Robert C Stauffer
NPI 1265478390
$8,055.15
in general payments reported to CMS, 2019-2025
23 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $1,621 · 2021: $418 · 2022: $380 · 2023: $3,300 · 2024: $587 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324 · Travel and Lodging: $1,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,324.36 |
| Travel and Lodging | $1,736.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,609.97 | 2019-2024 | Ekosonic |
| Terumo Medical Corporation | $1,189.90 | 2020 | |
| Abbott Laboratories | $518.51 | 2019-2025 | Coroflow, Esprit, Jeti Peripheral Catheter |
| Abiomed | $472.97 | 2019-2025 | Impella |
| Medtronic Vascular, INC. | $458.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $241.84 | 2024-2025 | |
| Philips North America LLC | $225.27 | 2023-2024 | (Br5) Peripheral Ivus, (792) Multi Modality Ivus Other Systems |
| Medtronic, INC. | $211.32 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Cobalt Dr Mri Surescan |
| Shockwave Medical, INC | $175.24 | 2022 | |
| Novo Nordisk INC | $154.20 | 2024-2025 | Wegovy |
| Penumbra, INC. | $147.74 | 2023 | Penumbra System |
| Cvrx, INC. | $137.67 | 2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.04 | 2019-2020 | |
| Pfizer INC. | $97.26 | 2024-2025 | |
| Biotronik INC. | $93.95 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $52.41 | 2025 | Alphavac |
| E.R. Squibb & Sons, L.L.C. | $44.59 | 2024-2025 | Eliquis, Camzyos |
| Bridgebio Pharma, INC. | $30.60 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $23.57 | 2025 | Wainua |
| Cardiovascular Systems INC. | $20.97 | 2022-2023 | Diamondback Coronary |
| Merck Sharp & Dohme LLC | $16.73 | 2023 | Verquvo |
| Amarin Pharma, INC. | $12.61 | 2021 | |
| Chiesi USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stauffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.